Short answer
Cytek Biosciences, Inc. (CTKB) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $53M (up 1.8% year over year) with net income of −$6M.
Q3 2026 key financials · XBRL
- Revenue
- $53M
- +1.8% YoY · +10.6% QoQ
- Net income
- −$6M
- −11.3% YoY · +49.9% QoQ
- Operating margin
- -15.8%
- Gross margin
- 58.6%
Source: XBRL data from the Cytek Biosciences, Inc. (CTKB) Q3 2026 10-Q on SEC EDGAR. USD.
Cytek Biosciences, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $53.2M, up 2% YoY from $52.3M, driven by service revenue $16.1M, up 13%
- Gross margin 59% vs 53% YoY, product margin 61% vs 53%, service margin 53% vs 51%
- Best performer: service revenue $16.1M, up $1.9M; weakest: product revenue $37.2M, down $1.0M
- Cash, equivalents, restricted cash and marketable securities $256.3M vs $261.5M at December 31, 2025; operating cash used $5.8M
- Near-term headwinds: biotech funding constraints, tariffs, export controls and potential NIH policy impacts on academic demand
Risk Factors
- New export-control risk: January 15, 2025 U.S. license requirements now cover certain flow cytometers and cell sorters exported to China
- Updated trade risk: Singapore and China tariff rates increased from 10% to 12.5%, potentially raising manufacturing costs
- New cybersecurity exposure: November 2025 security incident affected employee personal information
- Near-term demand risk: academic and government institutions generated 46% of revenue in Q3 2026, increasing exposure to NIH funding reductions
- Liquidity risk: existing cash expected to fund operating expenses for at least 12 months from the filing date
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Cytek Biosciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.